M
Maria Domenica Cappellini
Researcher at University of Milan
Publications - 570
Citations - 21441
Maria Domenica Cappellini is an academic researcher from University of Milan. The author has contributed to research in topics: Thalassemia & Deferasirox. The author has an hindex of 71, co-authored 518 publications receiving 18668 citations. Previous affiliations of Maria Domenica Cappellini include Centra & Vita-Salute San Raffaele University.
Papers
More filters
Journal ArticleDOI
Quality of Life and Satisfaction with Iron Chelation Therapy in Patients with Beta Thalassemia Major: Results from the ITHACA Study.
TL;DR: In this paper, the authors investigated the health-related quality-of-life (HRQoL) of patients with beta thalassemia major (TM) and their satisfaction with ICT.
Journal ArticleDOI
FRI-442-Acute hepatic porphyria disease manifestations and daily life impacts in EXPLORE international, prospective, natural history study
Laurent Gouya,Manisha Balwani,D. Montgomery Bissell,David C. Rees,Ulrich Stölzel,John D. Phillips,Raili Kauppinen,Janneke G. Langendonk,Robert J. Desnick,Jean Charles Deybach,Herbert L. Bonkovsky,Charles J. Parker,Hetanshi Naik,Michael Norman Badminton,Penelope E. Stein,Elisabeth I. Minder,Jerzy Windyga,Pavel Martásek,Maria Domenica Cappellini,Paolo Ventura,Eliane Sardh,Pauline Harper,Sverre Sandberg,Aasne K. Aarsand,Félix Alegre,Aneta Ivanova,Neila Talbi,John J. Ko,Dalia Cahana-Amitay,Amy Chan,Quinn Dinh,Craig Penz,Amy Simon,Tim Lin,Karl E. Anderson +34 more
Journal ArticleDOI
Rosette inhibition test in chronic liver disease
TL;DR: The rosette inhibition test for the evaluation of T-lymphocyte "sensitization" in patients with different chronic liver disorders found a cell-mediated immune reaction was found in 81% of patients with chronic active hepatitis and in 71% with primary biliary cirrhosis, whereas patients with Chronic persistent hepatitis showed no reaction.
Journal ArticleDOI
Selecting ß-Thalassemia Patients for Gene Therapy: A Decision-Making Algorithm
Donatella Baronciani,Maddalena Casale,Lucia De Franceschi,Giovanna Graziadei,Filomena Longo,Raffaella Origa,Valeria Pinto,Paolo Rigano,Monia Marchetti,Antonia Gigante,Emanuele Angelucci,Maria Domenica Cappellini,Achille Iolascon,Antonio Piga,Gian Luca Forni +14 more
TL;DR: The Italian Scientific Society for Thalassemias and Hemoglobinopathies (SITE) closely involved in the cure and overall approach to these pathologies, decided to carry out this project of analysis and assessment to establish the possible inclusion and exclusion criteria for access to GT of patients with β-TDT and to collect the outcomes.
Journal ArticleDOI
P1518: long-term safety results of the believe study of luspatercept in adults with βeta-thalassemia
Vip Viprakasit,Maria Domenica Cappellini,John B. Porter,K. Kuo,T. Coates,Ersi Voskaridou,V.M Pinto,Immacolata Tartaglione,Abderrahim Khelif,Alok Milton Lal,Antonis Kattamis,Antonio Piga,Olivier Hermine,Natalia Holot,Frederik Lersch,Jeevan K. Shetty,J. Zhang,Lesley S. Bueno,Ana Carolina Giuseppi,Dimana O. Miteva,Ali T. Taher +20 more
TL;DR: The phase 3, placebo-controlled BELIEVE trial was shown luspatercept to be well tolerated in patients with transfusion-dependent β -thalassemia, and among the treatment-emergent adverse events (TEAEs) more commonly associated with l Suspatercept were bone pain, arthralgia, dizziness, hypertension, and hyperuricemia.